



CORRECTION

Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]



Canhao Wu^{a,b,†}, Qin Xu^{a,†}, Huiyuan Wang^{b,*}, Bin Tu^{b,c},
Jiaxin Zeng^{a,b}, Pengfei Zhao^{b,d}, Mingjie Shi^b, Hong Qiu^{b,*},
Yongzhuo Huang^{b,c,e,f,*}

^aArtemisinin Research Center, First Clinical School, Guangzhou University of Chinese Medicine, Guangzhou 510450, China

^bState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

^cZhongshan Institute for Drug Discovery, SIMM, CAS, Zhongshan 528437, China

^dCenter of Clinical Pharmacology, the Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou 310009, China

^eNMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, Shanghai 201203, China

^fTaizhou University, School of Advanced Study, Institute of Natural Medicine and Health Product, Taizhou 318000, China

DOI of original article: <https://doi.org/10.1016/j.apsb.2021.09.004>.

*Corresponding authors.

E-mail addresses: wanghuiyuan@simm.ac.cn (Huiyuan Wang), hongqiu@simm.ac.cn (Hong Qiu), yzhuang@simm.ac.cn (Yongzhuo Huang).

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2023.08.007>

2211-3835 © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The authors regret in the initially published version of this article, there is a misapplied image in Fig. 3C. The corrected Fig. 3 is provided below.

The authors would like to apologize for any inconvenience caused.

The original Fig. 3 was:




Fig. 3 is revised as:

